Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.02 USD | -0.84% | -4.56% | -13.40% |
Jun. 03 | UroGen Pharma Appoints David Lin as New Chief Commercial Officer | CI |
May. 14 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.40% | 474M | |
+15.45% | 121B | |
+13.30% | 107B | |
-5.08% | 24.82B | |
+1.69% | 22.48B | |
-10.09% | 18.32B | |
-40.52% | 16.33B | |
-14.47% | 15.31B | |
+3.03% | 14.08B | |
+25.26% | 11.74B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- Berenberg Bank Initiates Coverage on UroGen Pharma With Buy Rating, $20 Price Target